Bioncotech

Bioncotech is a venture capital-backed clinical-stage immuno-oncology company with offices in Madrid and Valencia, Spain. They develop cutting-edge RNA-based therapies targeting novel validated targets in cancer and immune cells. Supported by a world-class team of scientific and clinical advisors, Bioncotech’s experienced drug development team is committed to delivering their therapies to patients in need.Bioncotech's lead drug, BO-112, induces immunogenic cell death in solid tumors while simultaneously activating the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. BO-112 triggers a robust immune response (turning “cold” tumors “hot”), shows high synergy with checkpoint inhibitors, and enables deep and durable anti-tumor responses. BO-112 is currently being studied in clinical trials both as a monotherapy and in combination with checkpoint inhibitors.